Cost regulators in Scotland have approved NHS funding for four new medicines, expanding treatment options for lung cancer, iron excess, hepatitis C and chronic pain, but Janssen's Darzalex was rejected for multiple myeloma.
AstraZeneca has expanded a late-stage trial currently assessing a potential new immuno-oncology (IO) therapy combination for the first-line treatment of non-small cell lung cancer (NSCLC), to include extra endpoints for both the combo and monotherapy.
The National Institute for Health Research Efficacy and Mechanism Evaluation (EME) Programme is funding a new £1.5 million trial testing a combination of therapies to prevent rapture in patients with brittle bone disease.
US regulators have extended the review period for Eli Lilly and Incyte's baricitinib, a once-daily oral medicine submitted in January last year for the treatment of moderate to severe rheumatoid arthritis.
Open to pharma sales
representatives and sales managers, candidates in this prominent industry competition
are both nominated and judged by healthcare professionals. The PharmaTimes Sales
Awards therefore delivers truly
meaningful recognition for pharma sales professionals, from the people who
matter most: their customers.
The PharmaTimes International Clinical Researcher of the
Year 2017 offers unique career development opportunity for clinical researchers
worldwide. The deadline for entry essays is Tuesday 31 January, so don't delay!
Clinical researchers in the
Americas: you've got until February 8 to register to take part in this prestigious
competition that offers a unique career development opportunity. PharmaTimes Clinical Researcher of
the Year – The Americas is open for entry!
The BioIndustry Association is warning that proposals to change to the way medicines and other health technologies are evaluated for NHS use could actually stop the flow of new therapies reaching patients with very rare and complex diseases.
UK group Oxford Sciences Innovation (OSI), which funds businesses stemming from science and technology research at Oxford University, has announced a "pioneering partnership" with pharma giant Celgene.
Some patients with kidney cancer should soon be able to get easier access to Novartis' Afinitor on the NHS, after cost regulators backed moving the drug out of the Cancer Drug's Fund and into the routine care pathway